JP2003521900A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2003521900A5 JP2003521900A5 JP2001550379A JP2001550379A JP2003521900A5 JP 2003521900 A5 JP2003521900 A5 JP 2003521900A5 JP 2001550379 A JP2001550379 A JP 2001550379A JP 2001550379 A JP2001550379 A JP 2001550379A JP 2003521900 A5 JP2003521900 A5 JP 2003521900A5
- Authority
- JP
- Japan
- Prior art keywords
- protein
- cell population
- seq
- cells
- sequence represented
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 210000000130 stem cell Anatomy 0.000 description 36
- 238000000034 method Methods 0.000 description 34
- 102000004169 proteins and genes Human genes 0.000 description 33
- 108090000623 proteins and genes Proteins 0.000 description 33
- 210000004027 cell Anatomy 0.000 description 29
- 239000002773 nucleotide Substances 0.000 description 18
- 125000003729 nucleotide group Chemical group 0.000 description 18
- 125000003275 alpha amino acid group Chemical group 0.000 description 17
- 102100020718 Receptor-type tyrosine-protein kinase FLT3 Human genes 0.000 description 11
- 102000039446 nucleic acids Human genes 0.000 description 10
- 108020004707 nucleic acids Proteins 0.000 description 10
- 150000007523 nucleic acids Chemical class 0.000 description 10
- 235000021374 legumes Nutrition 0.000 description 9
- 102000005962 receptors Human genes 0.000 description 9
- 108020003175 receptors Proteins 0.000 description 9
- 230000000694 effects Effects 0.000 description 8
- 210000003958 hematopoietic stem cell Anatomy 0.000 description 8
- 239000008194 pharmaceutical composition Substances 0.000 description 8
- 244000046052 Phaseolus vulgaris Species 0.000 description 6
- 101710151245 Receptor-type tyrosine-protein kinase FLT3 Proteins 0.000 description 6
- 239000011324 bead Substances 0.000 description 6
- 238000002512 chemotherapy Methods 0.000 description 6
- 230000001225 therapeutic effect Effects 0.000 description 6
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 description 5
- 101000932478 Homo sapiens Receptor-type tyrosine-protein kinase FLT3 Proteins 0.000 description 5
- 239000000556 agonist Substances 0.000 description 5
- AOJJSUZBOXZQNB-TZSSRYMLSA-N Doxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-TZSSRYMLSA-N 0.000 description 4
- 102000004856 Lectins Human genes 0.000 description 4
- 108090001090 Lectins Proteins 0.000 description 4
- 241001465754 Metazoa Species 0.000 description 4
- 206010028980 Neoplasm Diseases 0.000 description 4
- 235000010627 Phaseolus vulgaris Nutrition 0.000 description 4
- 201000011510 cancer Diseases 0.000 description 4
- 150000001875 compounds Chemical class 0.000 description 4
- 238000000338 in vitro Methods 0.000 description 4
- 239000002523 lectin Substances 0.000 description 4
- 238000001959 radiotherapy Methods 0.000 description 4
- 230000000779 depleting effect Effects 0.000 description 3
- 239000000203 mixture Substances 0.000 description 3
- 239000007787 solid Substances 0.000 description 3
- 238000006467 substitution reaction Methods 0.000 description 3
- UHDGCWIWMRVCDJ-CCXZUQQUSA-N Cytarabine Chemical compound O=C1N=C(N)C=CN1[C@H]1[C@@H](O)[C@H](O)[C@@H](CO)O1 UHDGCWIWMRVCDJ-CCXZUQQUSA-N 0.000 description 2
- 235000007007 Dolichos lablab Nutrition 0.000 description 2
- GHASVSINZRGABV-UHFFFAOYSA-N Fluorouracil Chemical compound FC1=CNC(=O)NC1=O GHASVSINZRGABV-UHFFFAOYSA-N 0.000 description 2
- 240000008892 Helianthus tuberosus Species 0.000 description 2
- 235000003230 Helianthus tuberosus Nutrition 0.000 description 2
- 101001046686 Homo sapiens Integrin alpha-M Proteins 0.000 description 2
- 102100022338 Integrin alpha-M Human genes 0.000 description 2
- 102100022297 Integrin alpha-X Human genes 0.000 description 2
- 101100013466 Lablab purpureus FRIL gene Proteins 0.000 description 2
- 244000046095 Psophocarpus tetragonolobus Species 0.000 description 2
- 244000213793 Sphenostylis stenocarpa Species 0.000 description 2
- 235000011989 Sphenostylis stenocarpa Nutrition 0.000 description 2
- 235000010724 Wisteria floribunda Nutrition 0.000 description 2
- 238000007792 addition Methods 0.000 description 2
- 210000002798 bone marrow cell Anatomy 0.000 description 2
- 230000000295 complement effect Effects 0.000 description 2
- 229960000684 cytarabine Drugs 0.000 description 2
- 238000012217 deletion Methods 0.000 description 2
- 230000037430 deletion Effects 0.000 description 2
- 229960004679 doxorubicin Drugs 0.000 description 2
- 229960002949 fluorouracil Drugs 0.000 description 2
- 230000013595 glycosylation Effects 0.000 description 2
- 238000006206 glycosylation reaction Methods 0.000 description 2
- 239000002243 precursor Substances 0.000 description 2
- 238000004321 preservation Methods 0.000 description 2
- 102100031585 ADP-ribosyl cyclase/cyclic ADP-ribose hydrolase 1 Human genes 0.000 description 1
- -1 CD11c Proteins 0.000 description 1
- 102100031573 Hematopoietic progenitor cell antigen CD34 Human genes 0.000 description 1
- 101000777636 Homo sapiens ADP-ribosyl cyclase/cyclic ADP-ribose hydrolase 1 Proteins 0.000 description 1
- 101000777663 Homo sapiens Hematopoietic progenitor cell antigen CD34 Proteins 0.000 description 1
- 101000851018 Homo sapiens Vascular endothelial growth factor receptor 1 Proteins 0.000 description 1
- 101000851007 Homo sapiens Vascular endothelial growth factor receptor 2 Proteins 0.000 description 1
- 108010053100 Vascular Endothelial Growth Factor Receptor-3 Proteins 0.000 description 1
- 102100033178 Vascular endothelial growth factor receptor 1 Human genes 0.000 description 1
- 102100033177 Vascular endothelial growth factor receptor 2 Human genes 0.000 description 1
- 102100033179 Vascular endothelial growth factor receptor 3 Human genes 0.000 description 1
- 230000001270 agonistic effect Effects 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 210000000988 bone and bone Anatomy 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 210000001671 embryonic stem cell Anatomy 0.000 description 1
- 230000003511 endothelial effect Effects 0.000 description 1
- 210000004700 fetal blood Anatomy 0.000 description 1
- 230000001605 fetal effect Effects 0.000 description 1
- 238000000684 flow cytometry Methods 0.000 description 1
- 108020001507 fusion proteins Proteins 0.000 description 1
- 102000037865 fusion proteins Human genes 0.000 description 1
- 210000003566 hemangioblast Anatomy 0.000 description 1
- 210000003494 hepatocyte Anatomy 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 210000002901 mesenchymal stem cell Anatomy 0.000 description 1
- 102000027426 receptor tyrosine kinases Human genes 0.000 description 1
- 108091008598 receptor tyrosine kinases Proteins 0.000 description 1
- 238000009877 rendering Methods 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| PCT/US1999/031307 WO2001049851A1 (en) | 1999-12-30 | 1999-12-30 | Progenitor cell preservation factors and related methods and products |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2003521900A JP2003521900A (ja) | 2003-07-22 |
| JP2003521900A5 true JP2003521900A5 (enExample) | 2007-03-22 |
Family
ID=22274423
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2001550379A Pending JP2003521900A (ja) | 1999-12-30 | 1999-12-30 | 前駆細胞保存因子、並びに関連する方法および産物 |
Country Status (10)
| Country | Link |
|---|---|
| EP (1) | EP1246919B1 (enExample) |
| JP (1) | JP2003521900A (enExample) |
| CN (1) | CN1406280A (enExample) |
| AT (1) | ATE302848T1 (enExample) |
| AU (1) | AU784361C (enExample) |
| CA (1) | CA2395625A1 (enExample) |
| DE (1) | DE69926920T2 (enExample) |
| ES (1) | ES2249058T3 (enExample) |
| HK (1) | HK1050027B (enExample) |
| WO (1) | WO2001049851A1 (enExample) |
Families Citing this family (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20020132017A1 (en) | 1996-12-09 | 2002-09-19 | Moore Jeffrey G. | Composition and method for preserving progenitor cells |
| EP2236156A3 (en) | 2001-01-09 | 2011-01-05 | Baylor Research Institute | Methods for treating and diagnosing Psoriasis |
| JP2004527495A (ja) * | 2001-02-27 | 2004-09-09 | ファイロジックス・エルエルシー | 組織および細胞を損傷から保護するための、そして損傷した組織を修復するための、組成物および方法 |
| WO2005046613A2 (en) * | 2003-11-12 | 2005-05-26 | Morningside Venture Investments Limited | Methods and compositions for the treatment of b cell lymphomas and other cancers |
| EP1901766A2 (en) * | 2005-04-08 | 2008-03-26 | Morningside Venture Investments Limited | Use of fril proteins for reducing the production of pro-inflammatory cytokines |
| JP2010516239A (ja) | 2007-01-18 | 2010-05-20 | スオメン プナイネン リスティ，ヴェリパルベル | 細胞の産生に対する新規方法および試薬 |
| CA2691787A1 (en) | 2007-06-29 | 2009-01-08 | The Trustees Of The University Of Pennsylvania | Soft gel systems in modulating stem cell development |
| WO2012048298A2 (en) | 2010-10-08 | 2012-04-12 | Caridianbct, Inc. | Methods and systems of growing and harvesting cells in a hollow fiber bioreactor system with control conditions |
| JP6247472B2 (ja) * | 2013-08-06 | 2017-12-13 | 日本メナード化粧品株式会社 | 幹細胞の未分化状態維持剤及び増殖促進剤 |
| WO2015073918A1 (en) | 2013-11-16 | 2015-05-21 | Terumo Bct, Inc. | Expanding cells in a bioreactor |
| US11008547B2 (en) | 2014-03-25 | 2021-05-18 | Terumo Bct, Inc. | Passive replacement of media |
| WO2016049421A1 (en) | 2014-09-26 | 2016-03-31 | Terumo Bct, Inc. | Scheduled feed |
| WO2017004592A1 (en) | 2015-07-02 | 2017-01-05 | Terumo Bct, Inc. | Cell growth with mechanical stimuli |
| US11965175B2 (en) | 2016-05-25 | 2024-04-23 | Terumo Bct, Inc. | Cell expansion |
| US11685883B2 (en) | 2016-06-07 | 2023-06-27 | Terumo Bct, Inc. | Methods and systems for coating a cell growth surface |
| US11104874B2 (en) | 2016-06-07 | 2021-08-31 | Terumo Bct, Inc. | Coating a bioreactor |
| US11629332B2 (en) | 2017-03-31 | 2023-04-18 | Terumo Bct, Inc. | Cell expansion |
| US11624046B2 (en) | 2017-03-31 | 2023-04-11 | Terumo Bct, Inc. | Cell expansion |
| US12234441B2 (en) | 2017-03-31 | 2025-02-25 | Terumo Bct, Inc. | Cell expansion |
| GB2619893A (en) | 2021-03-23 | 2023-12-20 | Terumo Bct Inc | Cell capture and expansion |
| US12209689B2 (en) | 2022-02-28 | 2025-01-28 | Terumo Kabushiki Kaisha | Multiple-tube pinch valve assembly |
| CN114262683B (zh) * | 2022-03-01 | 2022-06-17 | 中国科学院动物研究所 | 一种表达vegfr3 d2多肽的细菌制剂及其构建方法和应用 |
| USD1099116S1 (en) | 2022-09-01 | 2025-10-21 | Terumo Bct, Inc. | Display screen or portion thereof with a graphical user interface for displaying cell culture process steps and measurements of an associated bioreactor device |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6455678B1 (en) * | 1996-04-26 | 2002-09-24 | Amcell Corporation | Human hematopoietic stem and progenitor cell antigen |
| US6084060A (en) * | 1996-12-09 | 2000-07-04 | Imclone Systems Incorporated | Composition and method for preserving progenitor cells |
| US6310195B1 (en) * | 1997-06-24 | 2001-10-30 | Imclone Systems Incorporated | Nucleic acid encoding a lectin-derived progenitor cell preservation factor |
-
1999
- 1999-12-30 AT AT99967798T patent/ATE302848T1/de not_active IP Right Cessation
- 1999-12-30 DE DE69926920T patent/DE69926920T2/de not_active Expired - Fee Related
- 1999-12-30 WO PCT/US1999/031307 patent/WO2001049851A1/en not_active Ceased
- 1999-12-30 AU AU24014/00A patent/AU784361C/en not_active Ceased
- 1999-12-30 CN CN99817102A patent/CN1406280A/zh active Pending
- 1999-12-30 ES ES99967798T patent/ES2249058T3/es not_active Expired - Lifetime
- 1999-12-30 HK HK03102128.8A patent/HK1050027B/en not_active IP Right Cessation
- 1999-12-30 EP EP99967798A patent/EP1246919B1/en not_active Expired - Lifetime
- 1999-12-30 JP JP2001550379A patent/JP2003521900A/ja active Pending
- 1999-12-30 CA CA002395625A patent/CA2395625A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2003521900A5 (enExample) | ||
| Rafii et al. | Efficient mobilization and recruitment of marrow-derived endothelial and hematopoietic stem cells by adenoviral vectors expressing angiogenic factors | |
| CA2330208A1 (en) | Compositions and methods for use in affecting hematopoietic stem cell populations in mammals | |
| US6013067A (en) | Methods for increasing hematopoietic cells | |
| JPH08511935A (ja) | 選択的細胞増殖 | |
| CA2653881C (en) | Methods of selecting stem cells and uses thereof | |
| JPH06508528A (ja) | インビトロ由来ヒト好中球前駆体細胞 | |
| JP5036546B2 (ja) | 胸腺特異的タンパク質 | |
| ES2409128T3 (es) | Procedimientos de mejora de anidamiento e injerto de células madre | |
| US8846393B2 (en) | Methods of improving stem cell homing and engraftment | |
| CN105722975A (zh) | 出生后造血内皮细胞及其分离和应用 | |
| JP4834291B2 (ja) | Ｓｔａｔ３活性化幹細胞 | |
| MXPA05010140A (es) | Uso de agonistas de receptor de quimiocina para trasplante de celulas madre. | |
| CN101517070A (zh) | 选择干细胞的方法及其用途 | |
| Lear et al. | Restoration of allograft responsiveness in B rats | |
| US20130287750A1 (en) | Method of selecting stem cells and uses thereof | |
| CN112608897A (zh) | 经移植前暴露于死亡配体的造血祖细胞的活化 | |
| Rashidi et al. | The influence of parathyroid hormone on the adult hematopoietic stem cell niche | |
| Su | Ex vivo expansion of hematopoietic stem and progenitor cells from umbilical cord blood: Cytokine combinations, platelet-derived growth factor and stromal cell support | |
| Hoffman | Human hematopoietic stem cells: potential use as tumor-free autografts after high-dose myeloablative cancer therapy | |
| Meagher et al. | Human umbilical cord blood cells: How useful are they for the clinician? | |
| Atoui | For Myocardial Regenerative Therapy | |
| Holyoake | Investigation of the Effects of In Vitro Cytokine Exposure on Short and Long Term Reconstituting Haemopoietic Stem and Progenitor Cells in a Murine Model | |
| NILSSON et al. | VLA-5 Haemopoietic themestry CD162 PRP CD117 stem cell | |
| Rill et al. | Gene Marking and Gene Therapy for Transplantation Medicine |